A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics

G. M. Ruggiero, V. Laini, M. C. Mauri, V. M S Ferrari, A. Clemente, F. Lugo, M. Mantero, G. Redaelli, D. Zappulli, F. Cavagnini

Research output: Contribution to journalArticle

Abstract

1. The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria. 2. 13 patients, mean weight 37.61 kg ± 9.80 SD, were treated with clomipramine at a mean dosage of 57.69 mg ± 25.79 SD; 10 patients, mean weight 40.90 kg ± 6.98 SD, were treated with fluoxetine at a mean dosage of 28.00 mg ± 10.32 SD; 12 patients, mean weight 38.41 kg ± 8.33 SD, were treated with amisulpride at a mean dosage of 50.00 mg ± 0.00 SD. 3. Clinical evaluation was carried out under single-blind condition at basal time and after three months by a structured clinical interview, the Eating Disorder Interview based on Long Interval Follow-up Evaluation (LIFE II BEI). 4. Patients treated with amisulpride showed a more significant increase (p=O.O16) of mean weight. Concerning weight phobia, body image disturbance and amenorrhoea, no significant difference resulted.

Original languageEnglish
Pages (from-to)1049-1059
Number of pages11
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume25
Issue number5
DOIs
Publication statusPublished - 2001

Keywords

  • Amisulpride
  • Clomipramine
  • Fluoxetine
  • Psychopharmacotherapy
  • Re-feeding treatment
  • Restricting anorexia nervose

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Fingerprint Dive into the research topics of 'A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics'. Together they form a unique fingerprint.

  • Cite this